A low level, Carryover Free, Covering Wide Range, LC-MS/MS Method for Quantitation of Semaglutide in Human Plasma

Importance of the Topic

Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue widely prescribed for type 2 diabetes and obesity management. Accurate quantification in human plasma at low concentrations is crucial for pharmacokinetic profiling, therapeutic monitoring, and new clinical applications, including neurodegenerative disease research. Traditional assays face challenges such as non-specific adsorption, high background noise, and analyte carryover, necessitating robust analytical solutions.

Objectives and Study Overview

The primary aim was to develop a sensitive, precise, and carryover-free LC-MS/MS method for semaglutide quantitation over a broad dynamic range (0.2–600 ng/mL). Key goals included achieving a low limit of quantification (LLOQ), validating linearity, accuracy, precision, and demonstrating suitability for pharmacokinetic studies under ICH M10 guidelines.

Methodology and Instrumentation

An optimized two-step sample preparation combined protein precipitation and solid-phase extraction to minimize matrix effects and nonspecific losses. Chromatographic separation used a Shim-pack Scepter Claris C8 column (100 × 2.1 mm, 3 µm) with a gradient elution of 1% formic acid in water (mobile phase A) and 1% formic acid in methanol:acetonitrile (1:1, mobile phase B) at 0.3 mL/min. MS detection employed multiple reaction monitoring (MRM) in positive electrospray ionization mode. Transitions of m/z 1029.2 → 1302.5 and 1029.2 → 1359.1 were selected based on collision energy optimization.

Main Results and Discussion

• LLOQ was established at 0.2 ng/mL with signal-to-noise ratio >10.
• Calibration over 0.2–600 ng/mL exhibited excellent linearity (R² ≥ 0.995) and accuracy within 85–115%.
• Intra- and inter-day precision (%RSD) remained below 7.9% across LLQC, LQC, MQC, and HQC levels.
• No significant carryover was detected: blank injection after ULOQ showed <20% LLOQ response.

The method achieved retention time reproducibility within ±0.1 min and specificity with negligible interference from plasma matrix.

Benefits and Practical Applications

This LC-MS/MS approach offers:

• High sensitivity and wide dynamic range for PK/PD studies.
• Carryover-free performance ensuring reliable batch analyses.
• Streamlined sample preparation adaptable to high-throughput workflows.

It is applicable in drug discovery, clinical trials, therapeutic drug monitoring, and bioequivalence studies.

Future Trends and Potential Applications

Advancements in microflow LC and high-resolution MS may further reduce sample volume requirements and enhance sensitivity. Integration with automated extraction and data processing pipelines will support large-scale clinical studies. Expanding this platform to other peptide therapeutics could accelerate translational research and personalized medicine.

Conclusion

A validated LC-MS/MS method using Shimadzu LCMS-8060NX and Nexera X3 with robust sample preparation delivers reliable, sensitive, and carryover-free quantitation of semaglutide in human plasma. This method meets regulatory standards and is poised for routine application in pharmacokinetic and clinical investigations.

Reference

1) ICH M10: Bioanalytical Method Validation and Study Sample Analysis